Does a Sevoflurane Preconditioning Have Cardioprotective Properties in Noncardiac Thoracic Surgery?
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- Enrollment
- 100
- Locations
- 1
- Primary Endpoint
- Troponin T
Study Overview
Brief Summary
It has been shown that the use of volatile anaesthetics, that are usually used to perform a general anesthesia, have cardioprotective properties. This has been shown in animal studies and in patients that underwent cardiac surgery. The aim of our study is to examine if Sevoflurane, a volatile anaesthetic, has this properties in patients undergoing lung surgery.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Prevention
- Masking
- Single (Participant)
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Lung surgery
- •ASA (American Society of Anesthesiologists) physical status 1-3
Exclusion Criteria
- •Disposition for malignant hyperthermia
- •Medication with ß-blocking drugs
- •Use of clonidin
Arms & Interventions
Sevoflurane
Patients receive Sevoflurane 1 MAC (minimal alveolar concentration) after induction of anesthesia with propofol, remifentanil and atracurium for 30 minutes as preconditioning.
Intervention: Sevoflurane (Drug)
TIVA
Patients received the standard total intravenous anesthesia (TIVA) with propofol, remifentanil and atracurium.
Intervention: TIVA (Drug)
Outcomes
Primary Outcomes
Troponin T
Time Frame: change of Troponin T levels preoperative and postoperative up to 40 hours after surgery
assessing a change in high sensitive Troponin T (5th generation) Level before and at six time points after surgery (right after surgery, every 8 hours up to 40 hours after surgery)
Secondary Outcomes
No secondary outcomes reported